Overview
Canadian clinical-stage drug development company repurposing DMT as a stroke recovery treatment and exploring psychedelic compounds for neurological indications. Their AP-188 program targets neuroplasticity following ischemic stroke.
More in Psychedelics
Latest industry news
ReVision Implant Secures €4 Million to Advance Next-Generation Visual Neuroprosthetics
2026-07-25 · Funding
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Advance Neuroscience Therapeutics
2026-07-24 · Funding
Science Corp. Launches Prima BCI Implant in Europe, Bringing Vision Restoration to a New Market
2026-07-23 · Product
First Able-Bodied Individuals Receive Brain-Computer Implants in Landmark Expansion of BCI Eligibility
2026-07-22 · Research
Company details
Category
🍄 Psychedelics
Location
Vancouver, Canada
Funding
Public · TSX-V
Website
algernonpharmaceuticals.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →